# BECTON DICKINSON & CO (BDX) Informational only - not investment advice. CIK: 0000010795 SIC: 3841 Surgical & Medical Instruments & Apparatus SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 38](/major-group/38/) > [SIC 3841 Surgical & Medical Instruments & Apparatus](/industry/3841/) Latest 10-K filed: 2025-11-25 SEC page: https://www.sec.gov/edgar/browse/?CIK=10795 Filing source: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm ## At a glance FY2025 · period end 2025-09-30 · filed 2025-11-25 · accession 0000010795-25-000099 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000010795.json | Metric | Value | FY | Provenance | | --- | ---: | ---: | --- | | Revenue | 21,840,000,000 USD | 2025 | verified | | Net income | 1,678,000,000 USD | 2025 | verified | | Assets | 55,325,000,000 USD | 2025 | verified | | Free cash flow | 2,670,000,000 USD | 2025 | computed | | Net margin | 7.68% | 2025 | computed | | Operating margin | 11.81% | 2025 | computed | | Revenue YoY | +8.24% | 2025 | computed | | ROE | 6.61% | 2025 | computed | Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity. Peer groups: [Medical devices and instruments](/compare/medical-devices/) · SIC 3841 Surgical & Medical Instruments & Apparatus No market price, no rating, no forecast on this site. Not investment advice. ## Peer comparisons including BDX - Medical devices and instruments: [peer review](/compare/medical-devices/) · [market-risk page](/compare/medical-devices/risk/) ### Peer percentile fingerprint | Ratio | BDX | Peer median | Percentile | N | | --- | ---: | ---: | ---: | ---: | | Net margin | 7.7% | -6.0% | 68 | 63 | | Operating margin | 11.8% | -2.7% | 71 | 63 | | Revenue growth | 8.2% | 13.6% | 30 | 64 | | FCF margin | 12.2% | 0.2% | 71 | 63 | | ROE | 6.6% | -9.1% | 61 | 58 | | ROA | 3.0% | -4.8% | 64 | 65 | | Liabilities / equity | 1.18 | 0.89 | 58 | 63 | | Current ratio | 1.11 | 3.23 | 2 | 65 | Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 3841 Surgical & Medical Instruments & Apparatus, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking. ## Selected Fundamentals | Metric | Value | Unit | FY | Filed | | --- | ---: | --- | ---: | --- | | Revenue | 21840000000 | USD | 2025 | 2025-11-25 | | Net income | 1678000000 | USD | 2025 | 2025-11-25 | | Assets | 55325000000 | USD | 2025 | 2025-11-25 | ## Financials Annual standardized facts from SEC companyfacts as of latest extracted filing date 2025-11-25. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000010795.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts. | Metric | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | | | | | 12,483,000,000 | 12,093,000,000 | 15,983,000,000 | 17,290,000,000 | 16,074,000,000 | 19,131,000,000 | 18,870,000,000 | 19,372,000,000 | 20,178,000,000 | 21,840,000,000 | | Net income | | | | | 976,000,000 | 1,100,000,000 | 311,000,000 | 1,233,000,000 | 874,000,000 | 2,092,000,000 | 1,779,000,000 | 1,484,000,000 | 1,705,000,000 | 1,678,000,000 | | Operating income | | | | | 1,430,000,000 | 1,522,000,000 | 1,509,000,000 | 1,760,000,000 | 912,000,000 | 2,250,000,000 | 2,282,000,000 | 2,111,000,000 | 2,397,000,000 | 2,579,000,000 | | Diluted EPS | | | | | 4.49 | 4.60 | 0.60 | 3.94 | 2.71 | 6.85 | 5.88 | 4.94 | 5.86 | 5.82 | | Operating cash flow | 1,693,000,000 | 1,717,000,000 | 1,746,000,000 | 1,730,000,000 | | | | | 2,937,000,000 | 4,126,000,000 | 2,471,000,000 | 2,990,000,000 | 3,844,000,000 | 3,430,000,000 | | Capital expenditures | | | | | 693,000,000 | 727,000,000 | 895,000,000 | 957,000,000 | 769,000,000 | 1,194,000,000 | 973,000,000 | 874,000,000 | 725,000,000 | 760,000,000 | | Dividends paid | | | | | 562,000,000 | 677,000,000 | 927,000,000 | 984,000,000 | 1,026,000,000 | 1,048,000,000 | 1,082,000,000 | 1,114,000,000 | 1,100,000,000 | 1,196,000,000 | | Share buybacks | | | | | 0.00 | 220,000,000 | 0.00 | 0.00 | 0.00 | 1,750,000,000 | 500,000,000 | 0.00 | 500,000,000 | 1,000,000,000 | | Assets | | | | | 25,586,000,000 | 37,734,000,000 | 53,904,000,000 | 51,765,000,000 | 54,012,000,000 | 53,866,000,000 | 52,934,000,000 | 52,780,000,000 | 57,286,000,000 | 55,325,000,000 | | Stockholders' equity | | | | | 7,633,000,000 | 12,948,000,000 | 20,994,000,000 | 21,081,000,000 | 23,765,000,000 | 23,677,000,000 | 25,282,000,000 | 25,796,000,000 | 25,890,000,000 | 25,390,000,000 | | Cash and cash equivalents | | | | | 1,541,000,000 | 14,179,000,000 | 1,140,000,000 | 536,000,000 | 2,825,000,000 | 2,283,000,000 | 1,006,000,000 | 1,416,000,000 | 1,717,000,000 | 641,000,000 | | Free cash flow | | | | | | | | | 2,168,000,000 | 2,932,000,000 | 1,498,000,000 | 2,116,000,000 | 3,119,000,000 | 2,670,000,000 | ### Ratios ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported. | Metric | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Net margin | | | | | 7.82% | 9.10% | 1.95% | 7.13% | 5.44% | 10.94% | 9.43% | 7.66% | 8.45% | 7.68% | | Operating margin | | | | | 11.46% | 12.59% | 9.44% | 10.18% | 5.67% | 11.76% | 12.09% | 10.90% | 11.88% | 11.81% | | Return on equity | | | | | 12.79% | 8.50% | 1.48% | 5.85% | 3.68% | 8.84% | 7.04% | 5.75% | 6.59% | 6.61% | | Return on assets | | | | | 3.81% | 2.92% | 0.58% | 2.38% | 1.62% | 3.88% | 3.36% | 2.81% | 2.98% | 3.03% | | Liabilities / equity | | | | | 2.35 | 1.91 | 1.57 | 1.46 | 1.27 | 1.28 | 1.09 | 1.05 | 1.21 | 1.18 | | Current ratio | | | | | 1.45 | 5.58 | 1.03 | 1.18 | 1.54 | 1.33 | 1.04 | 1.31 | 1.17 | 1.11 | ## As-reported value updates 7 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period. Ledger: /company/BDX/revisions/ ## Quarterly Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000010795.json. Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived. | Quarter | End date | Revenue | Net income | Diluted EPS | Method | | --- | --- | ---: | ---: | ---: | --- | | 2023-Q1 | 2022-12-31 | | | 1.70 | reported discrete quarter | | 2023-Q2 | 2023-03-31 | | | 1.53 | reported discrete quarter | | 2023-Q3 | 2023-06-30 | | | 1.36 | reported discrete quarter | | 2023-Q4 | 2023-09-30 | 5,087,000,000 | 108,000,000 | | derived Q4 = FY annual - nine-month YTD | | 2024-Q1 | 2023-12-31 | 4,706,000,000 | 281,000,000 | 0.96 | reported discrete quarter | | 2024-Q2 | 2024-03-31 | 5,045,000,000 | 537,000,000 | 1.85 | reported discrete quarter | | 2024-Q3 | 2024-06-30 | 4,990,000,000 | 487,000,000 | 1.68 | reported discrete quarter | | 2024-Q4 | 2024-09-30 | 5,437,000,000 | 400,000,000 | | derived Q4 = FY annual - nine-month YTD | | 2025-Q1 | 2024-12-31 | 5,168,000,000 | 303,000,000 | 1.04 | reported discrete quarter | | 2025-Q2 | 2025-03-31 | 5,272,000,000 | 308,000,000 | 1.07 | reported discrete quarter | | 2025-Q3 | 2025-06-30 | 5,509,000,000 | 574,000,000 | 2.00 | reported discrete quarter | | 2025-Q4 | 2025-09-30 | 5,891,000,000 | 493,000,000 | | derived Q4 = FY annual - nine-month YTD | | 2026-Q1 | 2025-12-31 | 5,252,000,000 | 382,000,000 | 1.34 | reported discrete quarter | | 2026-Q2 | 2026-03-31 | 4,714,000,000 | -311,000,000 | -1.11 | reported discrete quarter | | 2026-Q3 | 2026-06-30 | 4,983,000,000 | 377,000,000 | 1.37 | reported discrete quarter | ## Filed narrative (10-K & 10-Q) ## Business Verbatim Item 1 Business section from BDX's latest 10-K: [/company/BDX/business/](/company/BDX/business/). ## Risk Factors Verbatim Item 1A Risk Factors from BDX's latest 10-K: [/company/BDX/risk-factors/](/company/BDX/risk-factors/). ## Latest quarter (10-Q) Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/10795/000001079526000035/bdx-20260630.htm Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high Filing date: 2026-08-06 Report date: 2026-06-30 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes presented in this report. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. References to years throughout this discussion relate to our fiscal years, which end on September 30. Company Overview Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies and devices used by healthcare institutions, physicians, clinical laboratories, the pharmaceutical industry and the general public. On February 9, 2026, we completed the spin-off of our former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation (“Waters”) in a Reverse Morris Trust transaction (the “Transaction”). The historical results of the former Biosciences and Diagnostic Solutions business (which was previously BD’s Life Sciences segment), have been reflected as discontinued operations in our consolidated financial statements for all periods prior to the spin-off date of February 9, 2026. Additional disclosures regarding our spin-off of the former Biosciences and Diagnostic Solutions business are provided in Note 2 in the Notes to Condensed Consolidated Financial Statements. Effective October 1, 2025, our segment reporting structure was reorganized into five distinct, separately-managed segments, based on the nature of our product and service offerings. Post-separation, we eliminated the Life Sciences segment from our segment reporting structure and our new organizational structure is based upon the following four remaining worldwide segments: BD Medical Essentials (“Medical Essentials”), BD Connected Care (“Connected Care”), BD BioPharma Systems (“BioPharma Systems”), and BD Interventional (“Interventional”). Our prior-period segment amounts have been recast in the tables below to conform to the new segment structure and to the current-period segment income presentation, as further discussed in Note 8 in the Notes to Condensed Consolidated Financial Statements. BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. Beginning in fiscal 2026, we split our EMEA (Europe, the Middle East and Africa) region into two distinct regions, Europe and META (the Middle East, Turkey, and Africa), to better align with our organizational structure. We now organize our operations outside the United States as follows: Europe, META; Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, Australia and New Zealand); Latin America (which includes Mexico, Central America, the Caribbean and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East and Africa, Latin America and certain countries within Greater Asia. As discussed above, we have reorganized our businesses and entered a new strategy of growth across our segments. Under New BD, we remain focused on touching and improving more patient lives, creating greater value for our associates and delivering even more impact for our customers. Our New BD strategy, Excellence Unleashed, is anchored in three strategic priorities: “compete”, “innovate” and “deliver”. To “compete”, we are elevating our commercial capabilities to gain share in the fastest growing areas of the medical technology market and to deliver an exceptional customer experience. Our priority to “innovate” emphasizes bringing high-impact solutions to the market and executing a pipeline that is stronger, more focused and productivity-driven. As we “deliver”, we strive for operational excellence, particularly in areas including safety, quality, reliable supply and cash flow generation. Key Trends and Uncertainties Affecting Results of Operations Our operations, supply chain, suppliers and customers are exposed to various global macroeconomic factors and other risks which we continually evaluate to assess their potential impact to our operations and financial results. We have been experiencing, and may continue to experience, some adverse impact to our results of operations due to market dynamics in China, such as volume-based procurement programs (“VoBP”) and the government’s focus to contain its healthcare-related costs and to improve compliance of healthcare practitioners. Lower demand for vaccines has also adversely impacted our results of operations. The future demand for our products and services could be impacted by other factors including the deterioration of healthcare systems’ budgets. In general, major disruptions in the sourcing, manufacturing and distribution of our products could adversely impact our results of operations. The ongoing conflict in Iran and the Middle East region has not yet significantly impacted our global supply chain or distribution of our products. However, continued disruption of transportation lanes and global energy supplies, as well 32 as increases in global oil prices due to this conflict could adversely affect our supply chain costs, our ability to source raw materials and components, and our ability to deliver product to customers, which may adversely impact our results of operations and our financial condition. Tariffs, sanctions or other trade barriers imposed by the United States, or against the United States from countries in which we do business, could also adversely impact our supply chain costs, results of operations and our financial condition. Tariffs have adversely impacted our third quarter fiscal year 2026 operating expense and we continue to monitor international trade policy-related developments, including developments regarding refunds of certain tariffs, to assess their potential future impacts to our operations. Based upon the latest published tariffs that are currently in effect, we expect a continued adverse impact to operating expense for fiscal year 2026 and potentially beyond, primarily relating to any products (or components) imported from countries across our global supply chain which have no exemption opportunities. The ultimate impact of any existing or new tariffs or other changes in international trade policies is subject to a number of factors including, but not limited to, the duration of such tariffs, changes in tariff rates, the amount, scope and nature of the tariffs, any countermeasures that target countries may take, or any mitigating actions that may become available. While sourcing optimization and tariff exemptions for qualifying products are key aspects of our mitigation strategy, the timing of such or the ultimate results we will realize from these efforts are uncertain. In addition, while we have received refunds of certain tariffs, our tariff mitigation strategies have been, and may be further challenged, rejected or eliminated through legislation or other challenges, or may otherwise not be effective, which may impact the collectability of the remaining receivable we have recorded for exemption claims. We continue to invest in research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including strategic geographical expansion), and develop innovative new products, as well as continue to improve operating efficiency and organizational effectiveness. For additional information on risk factors that may impact our business, results of operations, financial condition and cash flows, see Part I, Item 1A. Risk Factors of our 2025 Annual Report on Form 10-K (the “2025 Annual Report”). Overview of Financial Results and Financial Condition For the three months ended June 30, 2026, worldwide revenues of $4.983 billion increased 5.4% from the prior-year period. This increase reflected the following impacts: [[GREPCENT_TABLE]] [["","Increase (decrease) in current-period revenues"],["Volume/other (a)","4.1","%"],["Pricing","0.3","%"],["Foreign currency impact","1.0","%"],["Increase in revenues from the prior-year period","5.4","%"]] [[/GREPCENT_TABLE]] (a) Volume/other includes revenues attributable to products and services. Cash flows from continuing operating activities were $2.104 billion in the first nine months of fiscal year 2026. At June 30, 2026, we had $864 million in cash and equivalents and short-term investments, including restricted cash. We continued to return value to our shareholders in the form of dividends and during the first nine months of fiscal year 2026, we paid cash dividends to common shareholders of $875 million. We also paid cash to repurchase approximately $2.250 billion of our common stock during the nine-month period. In connection with the Transaction, we received a $4 billion cash distribution which was used to fund our second quarter share repurchases and debt repayments, as further discussed in Notes 4 and 14 in the Notes to Condensed Consolidated Financial Statements. Each reporting period and given our worldwide operations, we face exposure to our results of operations from changes in foreign currencies. We calculate translational foreign currency impacts by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results, which allows us to compare results between periods as if exchange rates had remained constant period-over-period. The third quarter fiscal year 2026 impact of foreign currency on our revenues, which is primarily translational, is provided above. The translational impact on our earnings is provided further below. We evaluate our results of operations on both a reported and a foreign currency-neutral basis. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis, excluding translational foreign currency impacts, in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. We use results on a foreign currency-neutral basis as one measure to evaluate our performance. These results should be considered in addition to, not as a substitute for, results reported in 33 accordance with U.S. generally accepted accounting principles (“GAAP”). Results on a foreign currency-neutral basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP. Results of Operations Medical Essentials Segment The following summarizes third quarter Medical Essentials revenues by organizational unit: [[GREPCENT_TABLE]] [["","Three months ended June 30,"],["(Millions of dollars)","2026","","2025","","Total Change","","Estimated FX Impact","","FXN Change"],["Medication Delivery Solutions","$","1,164","","","$","1,132","","","2.8","%","","1.2","%","","1.6","%"],["Specimen Management","511","","","470","","","8.7","%","","1.7","%","","7.0","%"],["Total Medical Essentials Revenues","$","1,675","","","$","1,602","","","4.5","%","","1.3","%","","3.2","%"]] [[/GREPCENT_TABLE]] The Medical Essentials segment’s revenue growth in the third quarter of 2026 primarily reflected th [Excerpt truncated for page length; source filing is linked above.] ## Latest 10-K MD&A (excerpt) Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/bdx-20250930.htm Complete FY 2025 MD&A: /company/BDX/mda/fy2025/ Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high Filing date: 2025-11-25 Report date: 2025-09-30 Item 7.     Management’s Discussion and Analysis of Financial Condition and Results of Operations The following commentary should be read in conjunction with the consolidated financial statements and accompanying notes presented in this report. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. References to years throughout this discussion relate to our fiscal years, which end on September 30. Company Overview Description of the Company and Business Segments Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon three principal business segments, BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, Australia and New Zealand); Latin America (which includes Mexico, Central America, the Caribbean and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East and Africa (collectively referred to below as “EMA”), as well as, Latin America and certain countries within Greater Asia. As further discussed in Note 8 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, effective October 1, 2025, we reorganized our organizational units into five distinct, separately-managed segments, based on the nature of our product and service offerings. BD’s new organizational structure is based upon the following five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences, which remains a critical part of BD until the separation and combination of our Biosciences and Diagnostic Solutions business with Waters Corporation (“Waters”) is completed. Additional disclosures regarding the agreement to combine our Biosciences and Diagnostic Solutions business with Waters are provided in Note 1 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data. Strategic Objectives BD remains focused on delivering durable growth, creating shareholder value and making appropriate investments for the future. Our strategy is anchored in three key pillars: grow, simplify and empower. BD's management team aligns our operating model and investments with these key strategic pillars through continuous focus on the following underlying objectives: Grow •Accelerating innovation in smart devices, robotics, analytics, and artificial intelligence in order to enable new care settings, improve outcomes, streamline care workflows, and reduce costs within healthcare settings; •Focusing on a strong portfolio of core leading products, solutions and services that deliver greater benefits to patients, healthcare workers and researchers; •Investing in research and development that leads to and expands category leadership, as well as results in a robust product pipeline; •Leveraging our global scale in order to provide equitable access to affordable medical technologies around the world, including in under-resourced markets; 35 Table of Contents •Supplementing our internal growth through strategic acquisitions in faster growing market segments; and •Focusing on cash management and an efficient capital structure in order to drive balance sheet productivity and strong shareholder returns. Simplify •Driving operating effectiveness and margin expansion through deployment of our BD Excellence program to increase factory productivity and asset efficiencies; •Reducing complexity, increasing agility and improving customer experience by rationalizing our product portfolio, as well as by simplifying and optimizing our architecture and operating model; •Making strategic investments that prioritize a culture of quality and our quality management system to ensure we are a best-in-class, proactive quality-driven organization; •Enhancing customer experiences through the digitalization of internal processes and go-to-market approaches; •Collaborating across our supply chain to responsibly source materials and goods, as well as to reduce environmental impacts; and •Continuing our investments in an enterprise-wide renewable energy strategy to create more resilient operations. Empower •Fostering a purpose-driven culture with a focus on positive impact to all stakeholders–customers, patients, employees, shareholders and communities; •Cultivating an inclusive work environment that welcomes and celebrates diverse backgrounds and perspectives; •Growing and enabling talent through training, development and reskilling strategies; and •Driving sustainability initiatives within our organizational units to support enterprise-wide collaboration towards our sustainability strategy. In assessing the outcomes of these strategies as well as BD’s financial condition and operating performance, management generally reviews forecast data, monthly actual results, including segment sales, and other similar information. We also consider trends related to certain key financial data, including gross profit margin, selling and administrative expense, investment in research and development, return on invested capital, and cash flows. Proposed Combination of Our Biosciences and Diagnostic Solutions Business with Waters As noted above and as further discussed in Note 1 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, we entered into a definitive agreement on July 13, 2025 to combine our Biosciences and Diagnostic Solutions business with Waters in a transaction that is expected to create an innovative life science and diagnostics leader with pioneering technologies. 36 Table of Contents Acquisition of Edwards Lifesciences’ Critical Care Product Group On September 3, 2024, we completed the acquisition of Edwards Lifesciences’ Critical Care product group, which we renamed as BD Advanced Patient Monitoring (“Advanced Patient Monitoring”), for total consideration of $3.914 billion. Advanced Patient Monitoring is a global leader in advanced monitoring solutions that expands BD’s portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement our existing technologies serving operating rooms and intensive care units. BD reports the results associated with Advanced Patient Monitoring’s product offerings as a separate organizational unit within our Medical segment and additional disclosures relating to this acquisition are provided in Notes 11 and 16 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data. BD’s Divestitures In August 2023, we completed the sale of the Interventional segment's Surgical Instrumentation platform. The historical financial results for this platform have not been classified as a discontinued operation. In April 2022, we completed the separation and distribution of Embecta Corp., formerly BD's Diabetes Care business, into a separate, publicly-traded company. Historical financial results have been reflected as discontinued operations in our consolidated financial statements. Additional disclosures regarding the sale and separation are provided in Note 2 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data. Key Trends and Uncertainties Affecting Results of Operations Our operations, supply chain, suppliers and customers are exposed to various global macroeconomic factors and other risks which we continually evaluate to assess their potential impact to our operations and financial results. We have been experiencing, and may continue to experience, some adverse impact to our results of operations due to market dynamics in China, such as volume-based procurement programs (“VoBP”) and the government’s focus to improve compliance of healthcare practitioners. Also, reductions or delays in governmental research funding has caused customers for certain of our instruments to delay or forgo purchases of these products. Lower demand for vaccines has also adversely impacted our results of operations. The future demand for our products and services could be impacted by other factors including higher interest rates and the deterioration of healthcare systems’ budgets. Additionally, we have experienced, and may continue to experience, temporary shortages in supply of certain materials or components that are used in our products. The stable flow of global transport is critical to our operations and as such, events affecting the flow of logistics around the globe may adversely impact our supply chain and distribution channels. In general, major disruptions in the sourcing, manufacturing and distribution of our products could adversely impact our results of operations. Also, tariffs, sanctions or other trade barriers imposed by the United States, or against the United States from countries in which we do business, could adversely impact our supply chain costs, results of operations and our financial condition. Based upon the latest published tariffs that are currently in effect, we expect tariffs to adversely impact our operating expense for fiscal year 2026 and potentially beyond, primarily relating to any products (or components) imported from countries across our global supply chain which have no exemption opportunities. We continue to monitor international trade policy-related developments to assess their potential impacts to our operations. The ultimate impact of any existing or new tariffs or other changes in international trade policies is subject to a number of factors including, but not limited to, the duration of such tariffs, changes in tariff rates, the amount, scope and nature of the tariffs, any countermeasures that target countries may take, or any mitigating actions that may become available. While sourcing optimization and tariff exemptions for qualifying products are key 37 Table of Contents aspects of our mitigation strategy, the timing of such or the ultimate results we will realize from these efforts are uncertain. In addition, our tariff mitigation strategies may be challenged, rejected or eliminated through legislation or other challenges, or may otherwise not be effective. We continue to invest in research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including strategic geographical expansion), and develop innovative new products, as well as continue to improve operating efficiency and organizational effectiveness. For additional information on risk factors that may impact our business, results of operations, financial condition and cash flows, see Part I, Item 1A. Risk Factors. Summary of Financial Results Worldwide [Excerpt truncated for page length; the complete text is on the linked full-MD&A page.] Read the full FY 2025 MD&A: /company/BDX/mda/fy2025/ All MD&A years: /company/BDX/mda/ ## MD&A history Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page. - [FY 2024 MD&A](/company/BDX/mda/fy2024/): filed 2024-11-27; accession 0000010795-24-000084 (https://www.sec.gov/Archives/edgar/data/10795/000001079524000084/bdx-20240930.htm) - [FY 2023 MD&A](/company/BDX/mda/fy2023/): filed 2023-11-21; accession 0000010795-23-000098 (https://www.sec.gov/Archives/edgar/data/10795/000001079523000098/bdx-20230930.htm) - [FY 2022 MD&A](/company/BDX/mda/fy2022/): filed 2022-11-22; accession 0001628280-22-030686 (https://www.sec.gov/Archives/edgar/data/10795/000162828022030686/bdx-20220930.htm) - [FY 2021 MD&A](/company/BDX/mda/fy2021/): filed 2021-11-24; accession 0000010795-21-000091 (https://www.sec.gov/Archives/edgar/data/10795/000001079521000091/bdx-20210930.htm) ## Macro cross-references Indicators mapped to this company's SIC classification (industry 3841 Surgical & Medical Instruments & Apparatus) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim. - [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index - [TCU](/indicator/TCU/): Capacity Utilization: Total Index - [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities - [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product - [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity - [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate - [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private - [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/). All macro indicators: /indicators/ ## For LLMs & downloads Markdown twin: /company/BDX.md · JSON record: /company/BDX.json · verified financials: /company/BDX/financials.json / /company/BDX/financials.csv · machine TOC for the whole site: /llms.txt